PreludeDxTM Closes $20 Million in Funding to Advance Growth Initiatives and Development of Its Precision Medicine Portfolio

Evidity Health Capital to Join Board of Directors LAGUNA HILLS, Calif., March 22, 2022 /PRNewswire/– Prelude Corporation (PreludeDxTM), a leader in molecular diagnostics and precision medicine for early-stage breast cancer, today announced that it has closed a $20 million funding round led by Evidity Health Capital and joined by existing and new investors. Alejandro Sanchez,…

Read More

Akili Interactive, a Leader in Digital Medicine, to Become Publicly Traded Through Combination with Social Capital Suvretta Holdings Corp. I

Akili’s leading digital therapeutic platform combines science and technology to address cognitive impairments in patients, reimagining how central nervous system medicines are designed, developed, and delivered Transaction will support commercial launch of EndeavorRx®, a first-of-its-kind, FDA-cleared and CE-marked prescription digital therapeutic for pediatric ADHD, as well as advance clinical development pipeline across multiple neuropsychiatric diseases,…

Read More